Socioeconomic Factors Impact ASCT Completion, Clinical Outcomes in MCL: Yazeed Sawalha, MD

Video

The hematologist from Ohio State University Comprehensive Cancer Center–The James discussed the impact of socioeconomic factors on completion of autologous stem cell transplant in patients with mantle cell lymphoma.

This content originally appeared on our sister site, CancerNetwork.

Factors such as insurance type, treatment facility, and location are associated with chances of completing autologous stem cell transplant (ASCT), and education and race impact survival outcomes.

CancerNetwork® spoke with Yazeed Sawalha, MD, a hematologist at the Ohio State University Comprehensive Cancer Center–The James, to learn more about the impact of certain socioeconomic factors on the completion of and clinical outcomes in patients with mantle cell lymphoma.

Transcript:

We looked at the impact of demographics and socioeconomic factors on the use of ASCT, but also on clinical outcomes—specifically overall survival. We found that after adjusting for other factors, the type of insurance and specifically having private insurance rather than Medicare, as well as receiving treatment at an academic or research facility, and certain geographical locations are actually associated with higher chances of undergoing ASCT.

In terms of clinical outcomes and survival, we found that the type of insurance was also important here. In addition, higher education and income levels were also associated with superior survival, whereas Black race was associated with inferior survival.

Reference
Sawalha Y, Radivoyevitch T, Jia X, et al. The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma. Leukemia & Lymphoma. Published online September 15, 2021. doi:10.1080/10428194.2021.1978085
Related Videos
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
© 2024 MJH Life Sciences

All rights reserved.